Praesidia is developing a first in class Tunable Linker Platform that revolutionizes the ways to maximize the therapeutic potential of drugs. The tunable linkers are designed to deliver drug payloads with greater tissue specificity and reduced toxicity.
Doctors know how they can improve their patients’ standard of care.
All the current drug candidates in our pipeline are derived from deep dive into understanding the gaps the physicians find in their everyday SOC for patients. After developing the linker technology from concept to translational data of proof, we took the potential of our technology to the physicians. We prioritized our pipeline based on our discussions with KOLs and practicing neurooncologists, pulmonologists, immunooncologists and endocrinologists. This has resulted in first-in-class and best-in-class products that cater to improved efficacy, reduced toxicity as well as address unmet clinical needs.
We have come together with the overarching goal of improving the therapeutic outcome of drugs for patients and with an undeterrable motivation to make a positive impact on the society at large, Praesidia is an amalgamation of patient-focused science, successful organization development pedigree with proven value delivery record to investors.
After having worked in stealth mode from 2019-2021, Praesidia is now poised to establish their platform and product portfolio being developed in labs across USA, Canada and India.
Praesidia is a culmination of the two founders’ over 50 years of combined drug development experience. This encompasses new target and new drug discovery, recombinant protein molecule and monoclonal antibody design, as well as platform development. The R&D experience extends to complete drug development lifecycle: from cell line to process development to scaling up to large scale GMP Manufacturing for clinical studies and market. Our experience and expertise are exponentially enriched by the scientific co-founders and expanding team of advisors with prominent academic, industrial and clinical pedigrees.